Abstract
Peptides are small number (<50) of units of amino acids covalently linked by the peptide bond. They are smaller in size and lower in molecular weight (<10,000 daltons) than proteins. Peptides also lack tertiary structures. Therefore, they are less prone to immunogenicity. Because target-specific imaging using monoclonal antibodies has proven elusive, imaging using biologically active peptides has raised enthusiasm among scientists and clinicians. This interest is because of the wealth of molecular recognition technology and protein biochemistry that may be applied to the diagnosis of human disease by direct visualization of the specific disease sites. This technology has become possible with the recent advances in imaging devices, protein chemistry, and the understanding of the physiological and pathological roles of protein and peptides.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Snyder SM, Bennett JD. Neurotransmitter receptors in the brain: biochemical identification. Annu Rev Physiol 1976;38:153–175.
Yalow RS, Berson SA. Basic considerations and general considerations. In: Odele WD, Daughaday WH, eds. Principles of Competitive Protein Binding Assays. Philadelphia: Lippincott,1971:1.
Wong FCL, Ho B, Lu IG, et al. Affinity labeling of neuroreceptors using gamma rays. J Nucl Med 1993;34(5):26 (abstract).
Wagner HN, Barns HD, Dannals RJ, et al. Imaging human dopamine receptors in the human brain. Science 1983;221:1264–1266.
Wong DF, Wagner HN, Tune LE, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986;234:1558–1562.
Wong DF, Pearlson G, Tune LE, et al. In vivo measurements of D2 dopamine receptor abnormalities in drug-naive and treated manic depressive patients. J Nucl Med 1987;28:611 (abstract).
Kung HF, Slavi A, Chang W, et al. In vivo SPECT imaging of CNS D2 dopamine receptors: initial studies with iodine-123 IBZM in humans. J Nucl Med 1990;31:573–578.
Eckelman WC. The testing of putative receptor binding radiotracers in vivo. In: Diksic M, Reba RD, eds. Radiopharmaceuticals and Brain Pathology Studies with PET and SPECT. Boca Raton: CRC Press, 1982:42–62.
Vera DR, Krohn KA, Scheibe PO, et al. Identifiability analysis of an in vivo receptor-binding radiopharmacokinetic system. IEEG Trans Biomed Eng 1985;32(5):312–322.
Yung BCK, Wand GS, Blevins L, et al. In vivo assessment of dopamine receptor density in pituitary macroadenoma and correlation with in vitro assay. J Nucl Med 1993;34(5):133 (abstract).
Junck L, Olson BS, Ciliax BJ, et al. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding sites. Ann Neurol 1989; 26:752–758.
Raderer M, Bechereer A, Kurtaran A, et al. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111 CFT-103 immunoscintigraphy. J Nucl Med 1996; 37(9):1480–1487.
Starosta-Rubinstein S, Ciliax BJ, Penney JB, et al. Imaging of a glioma using peripheral benzodiazepine receptor ligands. Proc Natl Acad Sci USA 1980;84:891–895.
Price GW, Ahier RG, Hume SP, et al. In vivo binding to peripheral benzodiazepine binding sites in lesional rat brain: comparison between [-3H]-P/C11194 and [18F]-PK 14105 as markers for neuronal damages. J Neurochem 1990;55: 175–185.
McGuire AH, Dehdashti F, Siegel BA, et al. Positron tomographic assessment of 16α-F18-fluoro-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32:1526–1531.
Reubi JC, Krenning E, Lamberts SW, et al. Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol 1990;37(6):1073–1077.
Lambert SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog. J Steroid Biochem Mol Biol 1990; 37(60):1079–1082.
Bakker WH, Krenning EP, Breeman WA, et al. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity and in vivo application in animals. J Nucl Med 1990;31:1501–1509.
Faglia G, Bazzoni N, Spado X, et al. In vivo detection of somatostatin receptors in patients with functionless pituitary xadenomas by means of a radioiodinated analog of somatostatin I-123 SD2204–090. J Clin Endocrinol Metab 1991;73:850–856.
Krenning EP, Kwekkeboom DJ, Panwels S, et al. Somatostatin receptor scintigraphy. Nucl Med Ann 1995;15:1–50.
Buscail L, Delesque N, Estéve J, et al. Stimulation of toposine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 1994;91:2315–2319.
Smith-Jones PM, Stolz B, Borms C, et al. Ga67/Ga-68 [DFO] octreotide-a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro as preliminary in vivo studies. J Nucl Med 1994;35:317–325.
Blok D, Feitsma RIJ, Vermeij P, et al. Peptide radiopharmaceuticals in nuclear medicine. Eur J Nucl Med 1999;26:1511–1519.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wong, F.C.L., Kim, E.E. (2001). Peptide Receptor Imaging. In: Kim, E.E., Yang, D.J. (eds) Targeted Molecular Imaging in Oncology. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-3505-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3505-5_8
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4757-3507-9
Online ISBN: 978-1-4757-3505-5
eBook Packages: Springer Book Archive